Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 17, 2017 - Issue 5
Submit an article Journal homepage
364
Views
13
CrossRef citations to date
0
Altmetric
Review

Therapeutic outcomes of the LHRH antagonists

Athanasios DellisUniversity Department of Urology, Sismanglio General Hospital, Athens, Greece;University Department of Surgery, Areteion Hospital, Athens, GreeceView further author information
&
Athanasios PapatsorisUniversity Department of Urology, Sismanglio General Hospital, Athens, GreeceCorrespondence[email protected]
View further author information
Pages 481-488 | Received 20 Jul 2017, Accepted 01 Sep 2017, Published online: 11 Sep 2017

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Kamal Kant Sahu, Nishita Tripathi, Neeraj Agarwal & Umang Swami. (2022) Relugolix in the management of prostate cancer. Expert Review of Anticancer Therapy 22:9, pages 891-902.
Read now
Mohamad Moussa, Athanasios Papatsoris, Athanasios Dellis, Mohamed Abou Chakra & Charalampos Fragkoulis. (2021) Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 22:17, pages 2373-2381.
Read now
Charalampos Fragkoulis, Ioannis Glykas, Athanasios Dellis, Iraklis Mitsogiannis & Athanasios Papatsoris. (2021) Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists. Arab Journal of Urology 19:4, pages 460-463.
Read now
Florence Thibaut, Paul Cosyns, John Paul Fedoroff, Peer Briken, Kris Goethals & John M. W. Bradford. (2020) The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. The World Journal of Biological Psychiatry 21:6, pages 412-490.
Read now

Articles from other publishers (9)

Mikel Goitia & Josep Estadella. (2023) Terapias emergentes en el tratamiento médico de los miomas uterinos. Medicina Clínica 161, pages S32-S37.
Crossref
Xin Li, Feifei Sun, Xiaolei Zhang, Pingping Lin, Kai Shen, Yu Shen, Lingyu Ma, Yu Cao & Chenjing Wang. (2023) Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study. BMC Medicine 21:1.
Crossref
Vaios-Konstantinos MytilekasEfstathios Papaefstathiou, Periklis Koukourikis, Xenofon OuzounidisStavros KazantzidisKonstantinos Hatzimouratidis. (2023) Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study. Investigative and Clinical Urology 64:6, pages 572.
Crossref
Jiten Jaipuria, Ishleen Kaur, Mohammad Najmud Doja, Tanvir Ahmad, Amitabh Singh, Sudhir Kumar Rawal, Vineet Talwar & Girish Sharma. (2023) Comparative analysis of real-world data of frequent treatment sequences in metastatic prostate cancer. Current Urology Publish Ahead of Print.
Crossref
J. Estadella Tarriel, J. Perelló Capó & R. Muñoz Sánchez. (2023) Actualización sobre las posibilidades de tratamiento médico hormonal para el sangrado menstrual abundante. Clínica e Investigación en Ginecología y Obstetricia 50:1, pages 100819.
Crossref
Maria Yu Konoshenko, Olga E. Bryzgunova & Pavel P. Laktionov. (2021) miRNAs and androgen deprivation therapy for prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188625.
Crossref
Sunil R BavaskarMayur R. Bhurat. (2021) Relugolix is the first and currently only Orally-Administered GnRH Receptor Antagonist Approved for the treatment of Prostate Cancer: A Review. Asian Journal of Pharmaceutical Research, pages 247-250.
Crossref
Fred Saad & Neal D. Shore. (2021) Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592199858.
Crossref
Hilal Saraç, Artem Cherkasov & Nathan A. Lack. 2021. Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance. Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance 23 46 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.